ISRCTN22931534已完成不适用
Tolerance, Physical and immunological response in Human Immunodeficiency Virus (HIV) seropositive persons supplemented daily with PMG151: Double blind, randomised controlled clinical trial
Centre for Traditional Medicine and Integrated Care (Centre de Medecine Traditionelle et de Soins integrés [CMTSI]) (Burkina Fas0 个研究点目标入组 186 人开始时间: 2010年9月15日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 186
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. HIV1 seropositive persons
- •2. Age between 18-55 years
- •3. Written informed consent given
- •4. Live in the study area for 12 next months
排除标准
- •1. Pregnant and/or lactating females
- •2. HIV2 seropositive or HIV1 and HIV2 coinfection
- •3. High blood pressure (Hypertension)
- •4. Cardiac or renal disease
- •5. History of known sickle cell disease
- •6. Alcohol abuse
研究者
相似试验
已完成
不适用
Tolerance and immunological response in human immunodeficiency virus (HIV) seropositive individuals after NR100063 supplementatioHuman immunodeficiency virus (HIV)Infections and InfestationsHuman immunodeficiency virusISRCTN30730587Danone Research B.V. (Netherlands)60
招募中
4 期
Immunologic response to hepatitis B immunization in children post liver transplantatioSafety and efficacy of hepatitis B vaccine, standard compare to double dose in short and long term follow-up.infection, bleeding, painTCTR20180723002Chulalonkorn University72
已完成
4 期
Safety, tolerability, and antibody response after intradermal vaccination of COVID-19 vaccine; PFE-BNT in adults who have completed two-doses of Verocell (inactivated vaccine)ocal reactions and systemic reactions after ID injection of PFE-BNT , antibody response after ID injection of PFE-BNTimmunogenicityside effectsTCTR20211023002ampang Hospital42
招募中
3 期
Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.Assessing the immunological responses and adverse reactions elicited by the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccinationCOVID-19SAR-CoV-2 second booster doseheterologous vaccinationBNT162b2CoronaVachealthcare workersTCTR20221112001The National Science Research and Innovation Fund340
进行中（未招募）
不适用
Immunogenicity, reactogenicity and safety of the trivalent influenza subunit vaccine Influvac® for the season 2009/2010. An open-label, baseline-controlled multi-center study in two groups: adult subjects =18 and =60 years and elderly subjects =61 years of age. - Influvac Annual Update 2009/2010EUCTR2009-010900-27-DESolvay Biologicals BV120